Inflammatory Pathways and Cholangiocarcinoma Risk Mechanisms and Prevention

Overview

Journal Adv Cancer Res

Publisher Elsevier

Specialty Oncology

Date 2022 Aug 12

PMID 35961707

Authors

Massimiliano Cadamuro

Mario Strazzabosco

Affiliations

Soon will be listed here.

Abstract

Cholangiocarcinoma (CCA), a neoplasm burdened by a poor prognosis and currently lacking adequate therapeutic treatments, can originate at different levels of the biliary tree, in the intrahepatic, hilar, or extrahepatic area. The main risk factors for the development of CCA are the presence of chronic cholangiopathies of various etiology. To date, the most studied prodromal diseases of CCA are primary sclerosing cholangitis, Caroli's disease and fluke infestations, but other conditions, such as metabolic syndrome, nonalcoholic fatty liver disease and obesity, are emerging as associated with an increased risk of CCA development. In this review, we focused on the analysis of the pro-inflammatory mechanisms that induce the development of CCA and on the role of cells of the immune response in cholangiocarcinogenesis. In very recent times, these cellular mechanisms have been the subject of emerging studies aimed at verifying how the modulation of the inflammatory and immunological responses can have a therapeutic significance and how these can be used as therapeutic targets.

Citing Articles

Gut Microbiome and Bile Acid Interactions: Mechanistic Implications for Cholangiocarcinoma Development, Immune Resistance, and Therapy.

Wu N, Bayatpour S, Hylemon P, Aseem S, Aseem S, Brindley P Am J Pathol. 2024; 195(3):397-408.

PMID: 39730075 PMC: 11841492. DOI: 10.1016/j.ajpath.2024.11.004.

Incidence and Long-Term Outcomes of Biliary Tract Cancers in Olmsted County, Minnesota from 1976 to 2018.

Nwankwo Jr E, Guta A, Cao S, Yang J, Abdalla A, Taha W Cancers (Basel). 2024; 16(15).

PMID: 39123448 PMC: 11311608. DOI: 10.3390/cancers16152720.

A Novel Bifidobacterium/Klebsiella Ratio in Characterization Analysis of the Gut and Bile Microbiota of CCA Patients.

Zhang N, Zhu W, Zhang S, Liu T, Gong L, Wang Z Microb Ecol. 2023; 87(1):5.

PMID: 38030815 PMC: 10687116. DOI: 10.1007/s00248-023-02318-3.

A Novel Mouse Model of Intrahepatic Cholangiocarcinoma Induced by Azoxymethane.

Shirakami Y, Kato J, Ohnishi M, Taguchi D, Maeda T, Ideta T Int J Mol Sci. 2023; 24(19).

PMID: 37834032 PMC: 10572168. DOI: 10.3390/ijms241914581.

References

Costa J, Vale N, Gouveia M, Botelho M, Sripa B, Santos L . Schistosome and liver fluke derived catechol-estrogens and helminth associated cancers. Front Genet. 2015; 5:444. PMC: 4274992. DOI: 10.3389/fgene.2014.00444. View

Zen Y, Harada K, Sasaki M, Chen T, Chen M, Yeh T . Intrahepatic cholangiocarcinoma escapes from growth inhibitory effect of transforming growth factor-beta1 by overexpression of cyclin D1. Lab Invest. 2005; 85(4):572-81. DOI: 10.1038/labinvest.3700236. View

Pinto C, Giordano D, Maroni L, Marzioni M . Role of inflammation and proinflammatory cytokines in cholangiocyte pathophysiology. Biochim Biophys Acta Mol Basis Dis. 2017; 1864(4 Pt B):1270-1278. DOI: 10.1016/j.bbadis.2017.07.024. View

Braconi C, Huang N, Patel T . MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology. 2010; 51(3):881-90. PMC: 3902044. DOI: 10.1002/hep.23381. View

Ilyas S, Yamada D, Hirsova P, Bronk S, Werneburg N, Krishnan A . A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma. J Biol Chem. 2016; 291(15):8031-47. PMC: 4825008. DOI: 10.1074/jbc.M115.698472. View

Matsumoto K, Onoyama T, Kawata S, Takeda Y, Harada K, Ikebuchi Y . Hepatitis B and C virus infection is a risk factor for the development of cholangiocarcinoma. Intern Med. 2014; 53(7):651-4. DOI: 10.2169/internalmedicine.53.1410. View

Michelotti A, de Scordilli M, Palmero L, Guardascione M, Masala M, Roncato R . NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. Cells. 2021; 10(8). PMC: 8391372. DOI: 10.3390/cells10082034. View

Karlsen T, Folseraas T, Thorburn D, Vesterhus M . Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017; 67(6):1298-1323. DOI: 10.1016/j.jhep.2017.07.022. View

Endo K, Yoon B, Pairojkul C, Demetris A, Sirica A . ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology. 2002; 36(2):439-50. DOI: 10.1053/jhep.2002.34435. View

10.

Banales J, Cardinale V, Carpino G, Marzioni M, Andersen J, Invernizzi P . Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016; 13(5):261-80. DOI: 10.1038/nrgastro.2016.51. View

11.

Kitano Y, Okabe H, Yamashita Y, Nakagawa S, Saito Y, Umezaki N . Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma. Br J Cancer. 2017; 118(2):171-180. PMC: 5785749. DOI: 10.1038/bjc.2017.401. View

12.

Smout M, Mulvenna J, Jones M, Loukas A . Expression, refolding and purification of Ov-GRN-1, a granulin-like growth factor from the carcinogenic liver fluke, that causes proliferation of mammalian host cells. Protein Expr Purif. 2011; 79(2):263-70. DOI: 10.1016/j.pep.2011.06.018. View

13.

Mederacke I, Hsu C, Troeger J, Huebener P, Mu X, Dapito D . Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013; 4:2823. PMC: 4059406. DOI: 10.1038/ncomms3823. View

14.

Rodrigues P, Olaizola P, Paiva N, Olaizola I, Agirre-Lizaso A, Landa A . Pathogenesis of Cholangiocarcinoma. Annu Rev Pathol. 2020; 16:433-463. DOI: 10.1146/annurev-pathol-030220-020455. View

15.

Wang X, Zhu W, Wang Z, Huang J, Wang S, Bai F . Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities. Theranostics. 2022; 12(1):260-276. PMC: 8690927. DOI: 10.7150/thno.63417. View

16.

Fabris L, Sato K, Alpini G, Strazzabosco M . The Tumor Microenvironment in Cholangiocarcinoma Progression. Hepatology. 2020; 73 Suppl 1:75-85. PMC: 7714713. DOI: 10.1002/hep.31410. View

17.

Sirica A, Gores G, Groopman J, Selaru F, Strazzabosco M, Wang X . Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances. Hepatology. 2018; 69(4):1803-1815. PMC: 6433548. DOI: 10.1002/hep.30289. View

18.

Isomoto H, Kobayashi S, Werneburg N, Bronk S, Guicciardi M, Frank D . Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology. 2005; 42(6):1329-38. DOI: 10.1002/hep.20966. View

19.

Trivedi P, Adams D . Mucosal immunity in liver autoimmunity: a comprehensive review. J Autoimmun. 2013; 46:97-111. DOI: 10.1016/j.jaut.2013.06.013. View

20.

Sugiura K, Mishima T, Takano S, Yoshitomi H, Furukawa K, Takayashiki T . The Expression of Yes-Associated Protein (YAP) Maintains Putative Cancer Stemness and Is Associated with Poor Prognosis in Intrahepatic Cholangiocarcinoma. Am J Pathol. 2019; 189(9):1863-1877. DOI: 10.1016/j.ajpath.2019.05.014. View